Applications of lung cancer organoids in precision medicine: from bench to bedside
Abstract As the leading cause of cancer-related mortality, lung cancer continues to pose a menacing threat to human health worldwide. Lung cancer treatment options primarily rely on chemoradiotherapy, surgery, targeted therapy, or immunotherapy. Despite significant progress in research and treatment...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Cell Communication and Signaling |
| Online Access: | https://doi.org/10.1186/s12964-023-01332-9 |
| _version_ | 1827590431652708352 |
|---|---|
| author | Huihui Li Zexin Chen Ning Chen Yun Fan Yaping Xu Xiaoling Xu |
| author_facet | Huihui Li Zexin Chen Ning Chen Yun Fan Yaping Xu Xiaoling Xu |
| author_sort | Huihui Li |
| collection | DOAJ |
| description | Abstract As the leading cause of cancer-related mortality, lung cancer continues to pose a menacing threat to human health worldwide. Lung cancer treatment options primarily rely on chemoradiotherapy, surgery, targeted therapy, or immunotherapy. Despite significant progress in research and treatment, the 5-year survival rate for lung cancer patients is only 10–20%. There is an urgent need to develop more reliable preclinical models and valid therapeutic approaches. Patient-derived organoids with highly reduced tumour heterogeneity have emerged as a promising model for high-throughput drug screening to guide treatment of lung cancer patients. Organoid technology offers a novel platform for disease modelling, biobanking and drug development. The expected benefit of organoids is for cancer patients as the subsequent precision medicine technology. Over the past few years, numerous basic and clinical studies have been conducted on lung cancer organoids, highlighting the significant contributions of this technique. This review comprehensively examines the current state-of-the-art technologies and applications relevant to the formation of lung cancer organoids, as well as the potential of organoids in precision medicine and drug testing. Video Abstract |
| first_indexed | 2024-03-09T01:16:46Z |
| format | Article |
| id | doaj.art-a75ef2b617c84ff9837244432d68595a |
| institution | Directory Open Access Journal |
| issn | 1478-811X |
| language | English |
| last_indexed | 2024-03-09T01:16:46Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell Communication and Signaling |
| spelling | doaj.art-a75ef2b617c84ff9837244432d68595a2023-12-10T12:26:24ZengBMCCell Communication and Signaling1478-811X2023-12-0121111310.1186/s12964-023-01332-9Applications of lung cancer organoids in precision medicine: from bench to bedsideHuihui Li0Zexin Chen1Ning Chen2Yun Fan3Yaping Xu4Xiaoling Xu5Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of SciencesGuangdong Research Center of Organoid Engineering and TechnologyDepartment of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of SciencesDepartment of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of SciencesDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of MedicineDepartment of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of MedicineAbstract As the leading cause of cancer-related mortality, lung cancer continues to pose a menacing threat to human health worldwide. Lung cancer treatment options primarily rely on chemoradiotherapy, surgery, targeted therapy, or immunotherapy. Despite significant progress in research and treatment, the 5-year survival rate for lung cancer patients is only 10–20%. There is an urgent need to develop more reliable preclinical models and valid therapeutic approaches. Patient-derived organoids with highly reduced tumour heterogeneity have emerged as a promising model for high-throughput drug screening to guide treatment of lung cancer patients. Organoid technology offers a novel platform for disease modelling, biobanking and drug development. The expected benefit of organoids is for cancer patients as the subsequent precision medicine technology. Over the past few years, numerous basic and clinical studies have been conducted on lung cancer organoids, highlighting the significant contributions of this technique. This review comprehensively examines the current state-of-the-art technologies and applications relevant to the formation of lung cancer organoids, as well as the potential of organoids in precision medicine and drug testing. Video Abstracthttps://doi.org/10.1186/s12964-023-01332-9 |
| spellingShingle | Huihui Li Zexin Chen Ning Chen Yun Fan Yaping Xu Xiaoling Xu Applications of lung cancer organoids in precision medicine: from bench to bedside Cell Communication and Signaling |
| title | Applications of lung cancer organoids in precision medicine: from bench to bedside |
| title_full | Applications of lung cancer organoids in precision medicine: from bench to bedside |
| title_fullStr | Applications of lung cancer organoids in precision medicine: from bench to bedside |
| title_full_unstemmed | Applications of lung cancer organoids in precision medicine: from bench to bedside |
| title_short | Applications of lung cancer organoids in precision medicine: from bench to bedside |
| title_sort | applications of lung cancer organoids in precision medicine from bench to bedside |
| url | https://doi.org/10.1186/s12964-023-01332-9 |
| work_keys_str_mv | AT huihuili applicationsoflungcancerorganoidsinprecisionmedicinefrombenchtobedside AT zexinchen applicationsoflungcancerorganoidsinprecisionmedicinefrombenchtobedside AT ningchen applicationsoflungcancerorganoidsinprecisionmedicinefrombenchtobedside AT yunfan applicationsoflungcancerorganoidsinprecisionmedicinefrombenchtobedside AT yapingxu applicationsoflungcancerorganoidsinprecisionmedicinefrombenchtobedside AT xiaolingxu applicationsoflungcancerorganoidsinprecisionmedicinefrombenchtobedside |